immx: the income statement

MyFinsight

For the quarter ending 2025-09-30, IMMX made $7,747,048 in revenue. -$7,588,260 in net income. Net profit margin of -97.95%.

Unit: Dollar

Income Statement	2025-09-30
General and administrative expenses	3,078,378
Research and development	4,584,131
Total operating expenses	7,662,509
Loss from operations	-7,662,509
Interest income	84,539
Total other expense, net	84,539
Loss before provision for income taxes	-7,577,970
Provision for income taxes	7,722
Net loss	-7,585,692
Net loss attributable to immix biopharma, inc. common stockholders	-7,585,692
Foreign currency translation	-2,568
Total other comprehensive loss	-2,568
Comprehensive loss	-7,588,260

Loss per common share - basic	-0.24
Loss per common share - diluted	-0.24
Weighted average shares outstanding - basic	31,926,651
Weighted average shares outstanding - diluted	31,926,651